View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
February 28, 2022

Kazia Therapeutics begins Phase II trial of paxalisib for glioblastoma in US

The open-label, two-arm trial will analyse the efficacy of paxalisib plus a ketogenic diet and metformin for glioblastoma.

Kazia Therapeutics has commenced a Phase II clinical trial of its investigational new drug, paxalisib, along with metformin and a ketogenic diet to treat recently diagnosed and recurrent glioblastoma, a type of primary brain cancer.

The trial was launched at Weill Cornell Medicine in the US, with the first subject initiated and a second participant in the screening stage.

Licenced by Kazia from Genentech in 2016, paxalisib is a brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway.

The open-label, two-arm trial will analyse the efficacy of paxalisib in combination with a ketogenic diet and metformin in patients with glioblastoma.

Cohort 1 of the trial will have subjects with recently detected glioblastoma with unmethylated MGMT promotor status.

Cohort 2 will enrol individuals with recurrent glioblastoma, irrespective of the methylation status of their MGMT promotor and have progressed following standard-of-care treatment.

Subjects in both cohorts will be given paxalisib plus metformin and a ketogenic diet.

Each arm will have two stages with nearly 16 subjects enrolled in the initial stage to identify initial signs of activity.

Nearly 15 subjects will be enrolled in the second confirmatory stage on confirming the activity.

The proportion of subjects who are alive and progression-free at six months will be the primary endpoint of the trial.

Apart from safety and efficacy, the trial will evaluate various metabolic, pharmacodynamic and new radiographic imaging biomarkers that could aid research and clinical practice in the future.

The company intends to conclude subject recruitment in the second half of CY2023.

Kazia Therapeutics CEO Dr James Garner said: “This important milestone kicks off an exciting year for Kazia, with at least six potential data read-outs anticipated over the course of 2022.

“The GBM AGILE study continues to progress well, and additional studies, such as this one, have the potential to substantially extend and enhance the use of paxalisib in clinical practice.”

The commencement of the latest trial for glioblastoma treatment takes the number of trials of paxalisib underway in brain cancer to a total of eight.

In December last year, the company reported positive data from a Phase II trial of paxalisib as a first-line therapy to treat glioblastoma.

Related Companies

Free Whitepaper

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy